DMITRIJ HRISTODOROV

Dmitrij Hristodorov serves as a distinguished Partner at Forbion, a prominent European venture capital firm dedicated to advancing the life sciences sector. In his pivotal role, Dmitrij is instrumental in identifying, evaluating, and nurturing groundbreaking early-stage and growth-stage companies within the drug discovery and development landscape. His strategic insights and deep industry expertise contribute significantly to Forbion's mission of building successful, innovative biotech companies that aim to deliver transformative medicines to patients worldwide.

Dmitrij's investment focus is broad yet targeted, encompassing novel therapeutic modalities across various disease areas. He possesses a keen interest in companies developing solutions for oncology, immunology, rare diseases, and neuroscience, always with an eye towards addressing substantial unmet medical needs. His approach combines rigorous scientific due diligence with a strong understanding of market dynamics, enabling him to pinpoint ventures with high potential for both scientific breakthrough and commercial success. He is particularly passionate about supporting entrepreneurs who are pushing the boundaries of biomedical science to create lasting impact.

Before joining Forbion in 2018, Dmitrij built a robust career foundation across both venture capital and the pharmaceutical industry. He previously held a significant position as a Principal at another respected life sciences venture capital firm, where he gained invaluable experience in deal sourcing, execution, and portfolio management. Prior to his venture capital career, Dmitrij honed his strategic and business development acumen at leading global pharmaceutical companies, including roles at Novartis and Roche. These experiences provided him with a comprehensive understanding of the drug development lifecycle, from early research to commercialization.

Academically, Dmitrij Hristodorov is exceptionally well-prepared for his role. He earned a PhD in Molecular Biology from the University of Zurich, providing him with a strong scientific bedrock. Further complementing his scientific expertise, he pursued an MBA from INSEAD, equipping him with sophisticated business and financial insights crucial for venture capital investment. This unique blend of scientific rigor and business acumen allows Dmitrij to effectively bridge the gap between cutting-edge research and viable commercial strategies.

Throughout his tenure at Forbion, Dmitrij has been actively involved in numerous investments that have bolstered the firm's impressive portfolio. While specific deal leadership is often a team effort, his contributions have been vital in shaping the growth trajectories of several innovative biotech companies. He works closely with portfolio company management teams, offering strategic guidance and leveraging his extensive network to accelerate their development. Dmitrij Hristodorov's dedication to fostering innovation and his commitment to the life sciences make him a key figure in the European biotech investment community.